Member of the Association of American Physicians
James A. Fagin mostly deals with Thyroid cancer, Cancer research, Thyroid, Internal medicine and Thyroid carcinoma. His Thyroid cancer study improves the overall literature in Cancer. His Cancer research research is multidisciplinary, incorporating perspectives in Mutation, Point mutation, Carcinogenesis, Carcinoma and MAPK/ERK pathway.
His study explores the link between Thyroid and topics such as Pathology that cross with problems in PAX8, Lumen and Extracellular matrix. His Internal medicine research includes themes of Endocrinology, Melanoma and Oncology. His research in the fields of RET/PTC Rearrangement and Poorly Differentiated Thyroid Carcinoma overlaps with other disciplines such as EIF1AX.
James A. Fagin focuses on Internal medicine, Cancer research, Thyroid cancer, Endocrinology and Thyroid. His Internal medicine research integrates issues from Cell culture, Messenger RNA, Oncology and Cell growth. James A. Fagin focuses mostly in the field of Cancer research, narrowing it down to matters related to Carcinogenesis and, in some cases, Molecular biology.
His Thyroid cancer research is multidisciplinary, relying on both Survival rate and Disease. His Endocrinology study integrates concerns from other disciplines, such as Receptor, Growth factor, Insulin-like growth factor and Gene expression. He works mostly in the field of Thyroid, limiting it down to concerns involving Pathology and, occasionally, Adenocarcinoma.
His main research concerns Thyroid cancer, Cancer research, Thyroid, Internal medicine and Mutation. His study in Thyroid cancer is interdisciplinary in nature, drawing from both Radiology, PTEN, Thyroid carcinoma and Disease. James A. Fagin has researched Cancer research in several fields, including Cancer, Tipifarnib, MEK inhibitor, Gene and HRAS.
His work in Thyroid addresses issues such as MAPK/ERK pathway, which are connected to fields such as Mutation, Germline mutation and Lysyl oxidase. His Internal medicine research incorporates elements of Endocrinology and Oncology. His Mutation research incorporates themes from Carcinogenesis, Melanoma, Chromatin remodeling, Kinase and In vivo.
Thyroid cancer, Internal medicine, Thyroid, Oncology and Cancer research are his primary areas of study. The concepts of his Thyroid cancer study are interwoven with issues in Pathology Report, Surgery, General surgery and Endocrine system. James A. Fagin is studying Thyroid carcinoma, which is a component of Internal medicine.
His Thyroid study deals with the bigger picture of Endocrinology. His research in Oncology intersects with topics in Survival rate and Cancer. His Cancer research study incorporates themes from Mutation, Downregulation and upregulation, Gene and Tipifarnib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal;Rehan Akbani;B. Arman Aksoy;Adrian Ally.
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Edna T. Kimura;Marina N. Nikiforova;Zhaowen Zhu;Jeffrey A. Knauf.
Cancer Research (2003)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells;Bruce G. Robinson;Robert F. Gagel;Henning Dralle.
Journal of Clinical Oncology (2012)
BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas
Marina N. Nikiforova;Edna Teruko Kimura;Manoj Gandhi;Paul W. Biddinger.
The Journal of Clinical Endocrinology and Metabolism (2003)
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer
Michael Mingzhao Xing;Ali S. Alzahrani;Kathryn A. Carson;David Viola.
Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules
Yuri E. Nikiforov;David L. Steward;Toni M. Robinson-Smith;Bryan R. Haugen.
The Journal of Clinical Endocrinology and Metabolism (2009)
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
J. A. Fagin;K. Matsuo;A. Karmakar;Dan Lin Chen.
Journal of Clinical Investigation (1993)
A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies.
James S. Forrester;Michael Fishbein;Richard Helfant;James Fagin.
Journal of the American College of Cardiology (1991)
Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.
Yuri E. Nikiforov;Jon M. Rowland;Kevin E. Bove;Hector Monforte-Munoz.
Cancer Research (1997)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Iñigo Landa;Tihana Ibrahimpasic;Laura Boucai;Rileen Sinha.
Journal of Clinical Investigation (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: